Equities

HUTCHMED (China) Ltd

HCM:LSE

HUTCHMED (China) Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)310.00
  • Today's Change0.00 / 0.00%
  • Shares traded17.44k
  • 1 Year change30.53%
  • Beta--
Data delayed at least 20 minutes, as of May 03 2024 16:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

  • Revenue in HKD (TTM)6.55bn
  • Net income in HKD787.36m
  • Incorporated2000
  • Employees1.99k
  • Location
    HUTCHMED (China) Ltd48Th Floor, Cheung Kong Center2 Queen's Road Central Hong KongHKG
  • Phone+852 21281188Fax+852 21281778
  • Websitehttps://www.hutch-med.com/
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.